It is known that wound healing involves several matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases at multiple levels of regulation. Retardation of wound healing is one of complications in diabetes mellitus due to increased collagenase activity and reduced granulation tissue in the diabetic wound.
I assay system was purchased from Amersham (Buckinghansire, England). The other chemiclas were of analytical grade.
Experimental Animals Three types of experiments were performed.
In Experiment 1 and Experiment 2, male Sprague Dawley rats, aged 5 weeks, were purchased from SLC (Shizuoka, Japan) and acclimatized in a temperature (22Ϯ2°C) and humidity (55Ϯ15%) controlled environments with a 12 h light/dark cycle for at least 6 d before use. They were allowed free access to laboratory chow (MF, Oriental yeast Co., Tokyo, Japan) and water. Animals aged 6 weeks were made diabetic by a single injection of STZ. Two sets of experiments were performed using Sprague Dawley rats. In one set of experiments for the wound healing study (Experiment 1), STZ was intraperitoneally injected at a dose of 65 mg/kg body weigh and animals with a blood glucose concentration greater than 300 mg/ml were assigned to the diabetic group 6 weeks after the administration of STZ. These rats were used for the wound healing study. At the end of the study, blood was collected from the descending vena cava under diethyl ether anesthesia. To one portion of blood was added sodium heparin at a final concentration of 20 units/ml for the separation of plasma. The other portion of the blood was centrifuged and the serum was separated. 17, 2007 ; published online May 24, 2007 In another set of experiments for the dose-response study (Experiment 2), STZ was intravenously injected at a dose of 60 mg/kg body weigh and rats with a blood glucose concentration greater than 300 mg/ml were assigned to the diabetic group 3 weeks after the injection of STZ. Three weeks after the diabetes induction, FYK-1388 was subcutaneously injected into the back of the animals at doses of 0.33, 1.0 and 3.33 mg/kg body weight three times a day (at 8:00, 16:00 and 0:00) (total doses of 1, 3 and 10 mg/kg body weight/d, respectively) for 14 d. Body weights, food comsumption and water intake were measured individually prior to drug administration and thereafter weekly. Two weeks after the treatment with FYK-1388, blood was collected from the descending vena cava under diethyl ether anesthesia, and, then, livers were removed. The blood was centrifuged to obtain serum.
Reducing Effect of Matrix Metalloproteinase Inhibitors on Serum Triacylglycerol in Streptozotocin-Induced Diabetic Rats and Zucker fa/fa Rats
In Experiment 3, male Zucker fa/fa rats and their lean litter mates aged 12 weeks were purchsed from Charles River Japan (Tokyo, Japan) acclimatized in a temperature (22Ϯ2°C) and humidity (55Ϯ15%) controlled environments with a 12 h light/dark cycle for 3 weeks before use. They were allowed free access to laboratory chow (MF, Oriental yeast Co., Tokyo, Japan) and water. Zucker fa/fa rats were given subcutaenous injections three times a day (at 8:00, 16:00 and 0:00) at a dose of 3.33 mg/kg body weight (total dose of 10 mg/kg body weight/d) for 14 d. Blood was collected collected from the descending vena cava under diethyl ether anesthesia and was centrifuged to obtain serum.
All animal experiments were conducted in accordance with the Guideline Principles for the Care and Use of Laboratory Animals established by Research Institute, Diichi Fine Chemical Co., Ltd.
Wound Healing Study Wound strength was measured by the method of Tsurumi et al. 4) with some modifications. Briefly, after shaving the dorsal skin full thickness incision skin wounds 15 mm in length were made on the back with a bone chisel. The wounds were closed with three equidistantly spaced sutures (No. 4.0 nylon) and the sutures were removed on day 3 after wounding. Fifteen days after wounding, the dorsal skin was excised, and cut into 6 mmϫ24 mm strips with the wound centrally located. The breaking strength of the strips was measured by rheometer (Rheotech Co., Ltd., Tokyo, Japan). The results were expressed as a maximal stress (g) placed across the wound before separation. The test compounds were dissolved in saline and sterilized by filtration (0.22 mm, Millex SV, Millipore Japan Co., Ltd., Tokyo, Japan). An osmotic pump (ALZET ® , DURECT Co., Cupertino, CA, U.S.A.) containing the test compound was subcutaneously implanted in the back at the same time as the wound was created. The test compounds were continuously infused at a dose of 3 mg/kg body weight/d for consecutive 15 d.
Measurement of Body Fat Mass Body fat mass was measured using a portable body fat meter (BE-9602, Medical Agent Inc., Kyoto, Japan) according to a bioelectrical impedance analysis method prior to and after the final administration of the test compound.
Determination of Serum Diagnostic Parameters Experiment 1: After the wound healing study, the concentrations of TG, cholesterol and glucose in serum were measured as follows. TG was determined enzymatically using diagnostic kits (IATRO-LQ TG) and the concentration of TG was corrected for free glycerol. Total cholesterol and glucose in serum were measured by colorimetric methods with diagnostic kits (IATRO-LQ T-CHO(A), and IATRO-LQ GLU).
Experiment 2: In the dose-response study, levels of TG, .120 and 1.006, were placed on the surface of the serum which was then placed in a centrifuge tube, and the tube was centrifuged at 10°C, 50000 rpm for 18-44 h (Optima XL-100K, Beckman Instrument Inc., CA, U.S.A.). The TG content in the VLDL fraction, and the cholesterol contents in the LDL and HDL fractions were measured by the method described above. Experiment 3: In th study using Zucker rats, levels of TG, chlesterol, phospholipid, glucose and insulin were determined by the daignostic kits. Serum insulin was measured by radioimmuno assay using a commercial kit Determination of Plasma MMPIs Plasma concentrations of MMPIs were determined by the method of Yamamoto et al. 5) Plasma MMPI concentrations were calculated as the MMP-3 inhibitory activity. The inhibitory activity was measured as follows. Pro MMP-3 was activated by incubation with (4-aminophenyl) mercuric acetate. The activated MMP-3 solution was diluted to 540 ng/ml with 50 mM Tris-HCl buffer (pH 7.5) containing 0.02% (w/v) bovine serum albumin, 0.15 M NaCl, 10 mM CaCl 2 , 0.05% (w/v) Brij 35 and 0.02% (w/v) NaN 3 . Substrate, 3168v, was dissolved in dimethly sulfoxide and diluted with the same buffer to a concentration of 60 mM. Plasma was filtered (UFC3LGC, Millipore Co., Ltd., Billerica, MA, U.S.A.) to remove molecules with a molecular weight over 30000. After pre-incubation of plasma (10 ml) and activated MMP-3 solution (50 ml) for 15 min, 3168v solution (50 ml) was added, and the mixture was incubated for 2 h. The reaction was stopped by adding 900 ml of 3% (v/v) acetic acid and the fluorescence intensity was measured at an excitation wavelength of 325 nm and an emission wavelength of 393 nm. The minimum detection levels of plasma MMPI were 10 nM for FYK-1388 and FYK-1352, and 20 nM for F61-1008.
Determination of Hepatic TG and Cholesterol Hepatic TG and cholesterol were extracted from livers by the method of Folch et al. 6 ) with some modification as described by Terada et al. 7) Total lipid extracted was dissolved in chloroform and an aliquot of the lipid extract was taken to dryness under N 2 . The residue was dissolved in 1-propanol Ϫ2% (v/v) Triton X-100 solution (3 : 20, v/v) and this solution was stirred at 70°C for 20 min then TG and cholesterol were measured with commercial kits as described above.
Statistical Analyses All statistical analyses were performed using Stat-View (SAS Institute, Cary, NC, U.S.A.). In Experiment 1 and 2, the statistical significance of the difference between normal control groups and the STZ induced-diabetic control groups was determined by Student's ttest or Aspin-Welch t-test after the F-test. In Experiment 1, 2 and 3, ANOVA was used to determine statistical significances of the difference between the STZ induced-diabetic control group and drug treated groups and the difference between Zucker fa/fa control group, Zucker fa/fa drug-treated group and Zucker lean group. When ANOVA indicated significant (p<0.05), Dunnett's multiple comparison was used as a post hoc analysis.
RESULTS

Effects of MMPIs on Wound Healing
To examine their effects on wound healing, MMPIs were continuously infused by osmotic pump for 15 d. As shown in Fig. 1A , the breaking wound strength in STZ-induced diabetic rats was significantly lower than that in non-diabetic rats. The administration of FYK-1388 and F61-1008 to STZ-induced diabetic rats at a dose of 3 mg/kg/d tended to increase the breaking wound strength, although the effects were not statistically significant. FYK-1352 did not increase the breaking wound strength. When these MMPIs were administered to STZ-induced diabetic rats at a dose of 3 mg/kg/d, the plasma concentrations of the MMPIs varied from 60 to 180 nM (Fig.  1B) . 
Effects of MMPIs on TG and Other Diagnostic Parameters in Serum of STZ-Induced Diabetic Rats
The serum levels of TG in the rats, which were used for the wound healing study, were measured. The serum concentrations of TG in STZ-induced diabetic rats were approximately 43 times higher than those of normal control rats. The administration of FYK-1388, FYK-1352 and F61-1008 to STZinduced diabetic rats significantly reduced the serum concentration of TG (Fig. 1C) . Among the MMPIs examined, FYK-1388 was the most effective and reduced the serum level of TG by approximately 80%. It is noteworthy that these treatments did not change the serum level of glucose (unpublished date). FYK-1388 also significantly reduced the serum concentration of cholesterol, whereas neither FYK-1352 nor F61-1008 had any effect (unpublished data).
In a further study of the effects of FYK-1388, normal and STZ-induced diabetic rats were subcutaneously injected with the compound at total doses of 1, 3 and 10 mg/kg body weight/d for 14 d. The body weight of the STZ-induced diabetic rats was lower than that of normal control rats by 30-40% during the dosing period. Food consumption and water intake in STZ-induced diabetic rats increased 1.6-1.7 and 7.3-7.7 times, respectively, as high as the values for normal rats. The mass of body fat in STZ-induced diabetic rats fell to 10-20% of the normal controls. FYK-1388 at any of the doses tested did not affect body weight, food consumption, water intake and mass of body fat in STZ-induced diabetic rats ( Table 2) .
The serum levels of TG and cholesterol in STZ-induced diabetic rats were 10 and 6 times higher than those of normal controls. Moreover, the concentrations of VLDL-TG and LDL-cholesterol in STZ-induced diabetic rats were 7 and 19 times higher, respectively, than those of normal controls. The administration of FYK-1388 to STZ-induced diabetic rats significantly reduced the concentrations of TG, cholesterol, VLDL-TG and LDL-cholesterol in a dose-dependent manner (Figs. 2, 3) . FYK-1388, at a dose of 3 mg/kg body weight, reduced the serum levels of TG, cholesterol, VLDL-TG and LDL-cholesterol by 70, 60, 65 and 67%, respectively. However, this compound did not change the serum level of HDLcholesterol (Fig. 3C) . The serum levels of glucose, free fatty acids, aspartate aminotransferase and alanine aminotransferase in STZ-induced diabetic rats were 2-3 times higher than those of normal controls. The treatment of rats with FYK-1388 affected serum levels of neither glucose nor free fatty acids; the increased slightly, but not significantly, serum 1464 Vol. 30, No. 8 levels of aspartate aminotransferase and alanine aminotransferase (Table 3) .
Effects of FYK-1388 on Hepatic TG and Cholesterol of STZ-Induced Diabetic Rats
The relative liver weights and hepatic content of TG and cholesterol in STZ-induced diabetic rats were 1.2-1.4 times higher than those of normal controls. These parameters were not influenced by the administration of FYK-1388 to STZ-induced diabetic rats (Table 4) .
Effects of FYK-1388 on TG and Cholesterol in Serum of Zucker fa/fa Rats Effects of FYK-1388 on serum levels of TG and cholesterol in Zucker fa/fa rats were examined (Table 5 ). Serum levels of TG and cholesterol in Zucker fa/fa rats were 9.9 and 3.4 times, respectively, higher than those in Zucker lean rats. The subcutaneous administration of FYK-1388 to Zucker fa/fa rats at a dose of 10 mg/kg body/d for 14 d reduced TG by 62.4%, cholesterol by 41.2% and phospholipid by 31.7%. The treatment with FYK-1388 did not affect body weight, mass of body fat, and the serum levels of glucose and insulin.
DISCUSSION
It is considered that breaking wound strength depends on a balance between synthesis and degradation of collagen and that several MMPs and tissue inhibitors of MMPs regulate the balance. It is likely, therefore, to suppose that inhibition of accelerated destructive activity of MMPs leads to wound healing, although the role of MMP in wound healing has not been precisely elucidated yet. Based on this hypothesis, in the present study, the effects of FYK-1388, FYK-1352 and F61-1008 on wound healing were investigated in STZ-induced diabetic rats using breaking wound strength as an index; however, no significant effect was observed. Moreover, the decreased content of collagen in wound tissue of STZ-induced diabetic rats was not recovered by the treatment with these MMPIs (unpublished data). One plausible expla- The animal treatments were the same as in Fig. 2 . A, VLDL-TG; B, LDL-cholesterol; C, HDL-cholesterol. a, normal rats; b, diabetic rats; c, diabetic rats plus FYK-1388 1 mg/kg; d, diabetic rats plus FYK-1388 3 mg/kg; e, diabetic rats plus FYK-1388 10 mg/kg. Values are the meansϮS.E. for 7 to 8 animals. Significantly different from normal control rats at * * p<0.01. Significantly different between diabetic control rats and diabetic rats treated with FYK-1388 at # p<0.05. nation for this unexpected results is that the concentrations of the MMPIs in the wound tissues were not kept high enough to inhibit MMPs in the present experimental conditions.
In the course of this study, a lower TG serum concentration was produced with the MMPIs. It should be noted here that the reduction in TG was marked and the MMPIs did not reduce the blood glucose level. Among the MMPIs examined, FYK-1388 was the most effective and produced an 80% reduction in serum TG level in STZ-induced diabetic rats. Detailed investigations showed that FYK-1388 reduced serum levels of TG, cholesterol, VLDL-TG and LDL-cholesterol in a dose-dependent manner. The treatment of STZ-induced diabetic rats with FYK-1388 did not affect body weight, food consumption, water intake, liver weight, mass of body fat, serum levels of glucose, free fatty acids, aspartate aminotransferase and alanine aminotransferase, and the hepatic content of TG and cholesterol. Therefore, the action of FYK-1388 on serum TG and cholesterol seems not to be due to any toxic effects of this compound. Moreover, FYK-1388 significantly lowered serum level of TG in Zucker fa/fa rats, which are genetically obese and hypertriglyceridemic. These results, taken together, indicate that FYK-1388 reduces serum level of TG in two diverse models of hyperlipidemia.
Several types of drugs have been reported to lower serum TG and these have been used clinically, such as fibrates, nicotinic acid and eicosapentanoic acid. Fibrates, such as bezafibrate, fenofibrate and clinofibrate, reduce serum TG and increase serum HDL.
8) The reducing effects of fibrates on serum TG are the most marked among hypolipidemic drugs. Peroxisome proliferator-activated receptor a, which is activated by specific agonists such as fibrates, plays an important role in regulating the metabolism of lipoproteins and fatty acids. [9] [10] [11] Through the binding to peroxisome proliferator-activated receptor a, fibrates enhance TG degradation, catabolisim of TG-rich lipoprotein and the b-oxidation of fatty acids, and suppress TG synthesis in the liver. Nicotinic acid reduces the serum levels of TG, cholesterol and apolipoprotein B, and increases the serum level of HDL. 12) This drug also inhibits fatty acid synthesis and suppresses the use of fatty acids in the liver through inhibition of lipolysis in the peripheral fat cells. Moreover, nicotinic acid inhibits fatty acid esterification in the liver by supressing diacylglycerol acyltransferase. Eicosapentanoic acid (EPA), a w3 polyunsaturated fatty acid, is present in high concentration in fish oil and reduces serum levels of TG and cholesterol. 13) EPA suppresses the absorption of TG via the intestine as well as the synthesis of fatty acids in the liver. 14) Moreover, EPA increases the activity of lipoprotein lipase in plasma, leading to accelerated removal of lipoprotein from the circulation. 15) Several studies have been reported concerning the relationship between the complications of dyslipidemia and MMPs. In particular, these previous studies suggested that the stability of atherosclerotic plaques correlated with the activities of tissue MMPs [16] [17] [18] and that treatment with hypolipidemic drugs affected the serum level of MMPs. 19, 20) To our knowledge, this is the first report showing the ability of MMPIs themselves to reduce serum levels of TG.
The information available to consider the mechanism by which the MMPIs examined in the present study lowered serum TG is very limited. Since the administration of FYK-1338 did not change either serum level of glucose in STZ-induced diabetic rats and serum levels of glucose and insulin in Zucker fa/fa rats (Tables 3, 5) , the possibility that FYK-1338 improved diabetic status to achieve the reduction of serum TG through the manipulation of serum concentration of insulin or hepatic sensitivity to insulin may be denied. In general, the mechanism of action of TG lowering drugs may be classified into 5 types, (i) inhibition of fatty acid synthesis and/or TG synthesis, (ii) inhibition of VLDL synthesis and/or secretion, (iii) removal of VLDL from circulation, (iv) inhibition of lipolysis in adipose tissues and (v) enhancement of degradation of fatty acid and/or TG. It should be noted, however, that these mechanisms are related to each other, so that they are not always separated clearly. The present results that the treatment of STZ-induced diabetic rats with FYK-1338 did not cause hepatic accumulation of TG (Table 4) suggest the possibility that the mechanisms (i), (ii) and /or (v) participate in the reduction of serum TG by the MMPI. Since the administration of FYK-1338 to STZ-induced diabetic rats and Zucker fa/fa rats did not lower the proportion of body fats (Tables 2, 5) , it is not plausible that FYK-1338 lowered serum TG by inhibiting lipolysis in adipose tissues (the mechanism (iv)). With regard to the mechanism (iii) such as an increase in activity of lipoprotein lipase, no infor- mation was obtained in the present study. It should be noted that since the chemical structures of MMPIs are very different from those of the other types of hypotriglyceridemic drugs mentioned above, the mechanism by which the MMPIs reduce serum concentrations of TG seems to be strikingly different from those of the TG reducing drugs that are used clinically. In this respect, MMPIs could become a novel type of TG-lowering drug.
